

# Nassim Kamar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8105554/publications.pdf>

Version: 2024-02-01

309  
papers

18,515  
citations

15880

67  
h-index

18400

124  
g-index

323  
all docs

323  
docs citations

323  
times ranked

13772  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 322-323.	2.6	120
2	Performance of creatinine-based equations to estimate glomerular filtration rate with a methodology adapted to the context of drug dosage adjustment. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2118-2127.	1.1	24
3	Incidence of cytomegalovirus infection in seropositive kidney transplant recipients treated with everolimus: A randomized, open-label, multicenter phase 4 trial. <i>American Journal of Transplantation</i> , 2022, 22, 1430-1441.	2.6	5
4	Anti-SARS-CoV-2 spike protein and neutralizing antibodies at 1 and 3 months after three doses of SARS-CoV-2 vaccine in a large cohort of solid organ transplant patients. <i>American Journal of Transplantation</i> , 2022, 22, 1467-1474.	2.6	37
5	Spectrum of Kidney Disorders Associated with T-Cell Immunoclonos. <i>Journal of Clinical Medicine</i> , 2022, 11, 604.	1.0	2
6	Niclosamide inhibits hepatitis E virus through suppression of NF-kappaB signalling. <i>Antiviral Research</i> , 2022, 197, 105228.	1.9	9
7	Acetate-Free Biofiltration Versus Online Acetate-Free Hemodiafiltration in Patients at High Risk of Hemodialysis Intolerance. <i>Kidney International Reports</i> , 2022, 7, 1108-1111.	0.4	1
8	Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, 690-701.	2.9	97
9	Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine. <i>Vaccines</i> , 2022, 10, 354.	2.1	8
10	Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 829-838.	3.0	23
11	Casirivimab-imdevimab to Prevent SARS-CoV-2 Infections in Solid Organ Transplant Recipients. <i>Transplantation</i> , 2022, 106, e275-e276.	0.5	8
12	Omicron breakthrough infection in a kidney transplant patient given pre-exposition casirivimab and imdevimab monoclonal antibodies. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	5
13	Impact of calcineurin inhibitor-free immunosuppression on de novo donor-specific antibody formation in liver transplant recipients. <i>Liver International</i> , 2022, 42, 1132-1143.	1.9	4
14	Impact of targeted hypothermia in expanded-criteria organ donors on recipient kidney-graft function: study protocol for a multicentre randomised controlled trial (HYPOREME). <i>BMJ Open</i> , 2022, 12, e052845.	0.8	1
15	Early Administration of Anti-SARS-CoV-2 Monoclonal Antibodies Prevents Severe COVID-19 in Kidney Transplant Patients. <i>Kidney International Reports</i> , 2022, 7, 1241-1247.	0.4	25
16	Monitoring and managing SARS-CoV-2 evolution in immunocompromised populations. <i>Lancet Microbe, The</i> , 2022, 3, e325-e326.	3.4	16
17	Predictive Factors for Humoral Response After 2-dose SARS-CoV-2 Vaccine in Solid Organ Transplant Patients. <i>Transplantation Direct</i> , 2022, 8, e1248.	0.8	25
18	Chronic hepatitis E: Advancing research and patient care. <i>Journal of Hepatology</i> , 2022, 77, 1109-1123.	1.8	37

#	ARTICLE	IF	CITATIONS
19	Cryptococcal Meningitis in Kidney Transplant Recipients: A Two-Decade Cohort Study in France. <i>Pathogens</i> , 2022, 11, 699.	1.2	6
20	Factors Associated With COVID-19 Vaccine Response in Transplant Recipients: A Systematic Review and Meta-analysis. <i>Transplantation</i> , 2022, 106, 2068-2075.	0.5	23
21	Identification of Predictive Markers and Outcomes of Late-onset <i>Pneumocystis jirovecii</i> Pneumonia in Kidney Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2021, 73, e1456-e1463.	2.9	20
22	Kidney transplantation during the COVID-19 pandemic: Potential long-term consequences of an early post-transplant infection. <i>Transplant Infectious Disease</i> , 2021, 23, e13446.	0.7	4
23	Trajectories of glomerular filtration rate and progression to end stage kidney disease after kidney transplantation. <i>Kidney International</i> , 2021, 99, 186-197.	2.6	40
24	Is COVID-19 infection more severe in kidney transplant recipients?. <i>American Journal of Transplantation</i> , 2021, 21, 1295-1303.	2.6	190
25	Development and Validation of a Modified Full Age Spectrum Creatinine-Based Equation to Estimate Glomerular Filtration Rate. <i>Annals of Internal Medicine</i> , 2021, 174, 183-191.	2.0	157
26	Determining the therapeutic range for ribavirin in transplant recipients with chronic hepatitis E virus infection. <i>Journal of Viral Hepatitis</i> , 2021, 28, 431-435.	1.0	7
27	Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation?. <i>American Journal of Transplantation</i> , 2021, 21, 1641-1649.	2.6	26
28	Antibiotics versus no therapy in kidney transplant recipients with asymptomatic bacteriuria (BiRT): a pragmatic, multicentre, randomized, controlled trial. <i>Clinical Microbiology and Infection</i> , 2021, 27, 398-405.	2.8	43
29	Temporal trends in living kidney donation in France between 2007 and 2017. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 730-738.	0.4	11
30	Comparison of two strategies based on mammalian target of rapamycin inhibitors in secondary prevention of non-melanoma skin cancer after kidney transplantation, a pilot study. <i>Clinical Transplantation</i> , 2021, 35, e14207.	0.8	4
31	Hepatitis E Infections in Transplants. , 2021, , 909-925.		0
32	External Validation of a Predictive Model to Estimate Renal Function After Living Donor Nephrectomy. <i>Transplantation</i> , 2021, Publish Ahead of Print, 2445-2450.	0.5	4
33	Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: Results of a nationwide study. <i>American Journal of Transplantation</i> , 2021, 21, 3021-3033.	2.6	8
34	Effector memory CD8 T cell response elicits Hepatitis E Virus genotype 3 pathogenesis in the elderly. <i>PLoS Pathogens</i> , 2021, 17, e1009367.	2.1	16
35	Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept. <i>Transplantation</i> , 2021, 105, e94-e95.	0.5	105
36	Living kidney donor evaluation for all candidates with normal estimated GFR for age. <i>Transplant International</i> , 2021, 34, 1123-1133.	0.8	3

#	ARTICLE	IF	CITATIONS
37	High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1704-1709.	0.4	87
38	Cytokine storm induced by a PD1 inhibitor in a renal transplant patient. <i>American Journal of Transplantation</i> , 2021, 21, 2616-2618.	2.6	8
39	Anti-SARS-CoV-2 Monoclonal Antibodies in Solid-organ Transplant Patients. <i>Transplantation</i> , 2021, 105, e146-e147.	0.5	24
40	Microsporidiosis after liver transplantation: A French nationwide retrospective study. <i>Transplant Infectious Disease</i> , 2021, 23, e13665.	0.7	3
41	Acute rejection after anti-SARS-CoV-2 mRNA vaccination in a patient who underwent a kidney transplant. <i>Kidney International</i> , 2021, 100, 238-239.	2.6	38
42	Clinical Utility of Biochemical Markers for the Prediction of COVID-19-Related Mortality in Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2021, 6, 2689-2693.	0.4	8
43	Kidney Failure after Liver Transplantation. <i>Transplantology</i> , 2021, 2, 315-335.	0.3	3
44	Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. <i>New England Journal of Medicine</i> , 2021, 385, 661-662.	13.9	728
45	Epidemiological and clinical study of microsporidiosis in French kidney transplant recipients from 2005 to 2019: TRANSPORE registry. <i>Transplant Infectious Disease</i> , 2021, 23, e13708.	0.7	5
46	Occurrence of severe COVID-19 in vaccinated transplant patients. <i>Kidney International</i> , 2021, 100, 477-479.	2.6	101
47	Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants. <i>Annals of Internal Medicine</i> , 2021, 174, 1336-1338.	2.0	122
48	Rat Hepatitis E Virus: Presence in Humans in South-Western France?. <i>Frontiers in Medicine</i> , 2021, 8, 726363.	1.2	8
49	Fatal encephalitis and Borna Disease Virus seropositivity in two kidney transplant patients living in the same nonendemic area. <i>Transplant Infectious Disease</i> , 2021, 23, .	0.7	5
50	Therapeutic education as a tool to improve patient-reported and clinical outcomes after renal transplantation: results of the EPHEGREN multicenter retrospective cohort study. <i>Transplant International</i> , 2021, 34, 2341-2352.	0.8	2
51	Adaptive lymphocyte profile analysis discriminates mild and severe forms of COVID-19 after solid organ transplantation. <i>Kidney International</i> , 2021, 100, 915-927.	2.6	4
52	Response to the KDOQI US Commentary on the 2018 KDIGO Hepatitis C Guideline. <i>American Journal of Kidney Diseases</i> , 2021, 77, 152.	2.1	3
53	Hepatitis E Virus Quasispecies in Cerebrospinal Fluid with Neurological Manifestations. <i>Vaccines</i> , 2021, 9, 1205.	2.1	8
54	Weekly high-dose liposomal amphotericin B prevents invasive aspergillosis after heart transplantation. <i>Transplant Infectious Disease</i> , 2021, , e13745.	0.7	0

#	ARTICLE	IF	CITATIONS
55	Dynamic prediction of renal survival among deeply phenotyped kidney transplant recipients using artificial intelligence: an observational, international, multicohort study. <i>The Lancet Digital Health</i> , 2021, 3, e795-e805.	5.9	25
56	New evidence shows it is time to stop unnecessary use of antibiotics in kidney transplant recipients with asymptomatic bacteriuria. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 754-756.	0.4	2
57	Assessment of 4 Doses of SARS-CoV-2 Messenger RNA-Based Vaccine in Recipients of a Solid Organ Transplant. <i>JAMA Network Open</i> , 2021, 4, e2136030.	2.8	103
58	Hemodynamic and Metabolic Tolerance of Acetate-Free Biofiltration in Mechanically Ventilated Critically Ill Patients: A Real-Life Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5729.	1.0	1
59	Outcomes of solid organ transplant recipients with invasive aspergillosis and other mold infections. <i>Transplant Infectious Disease</i> , 2020, 22, e13200.	0.7	9
60	Outcome of Liver Transplant Patients With Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies. <i>Liver Transplantation</i> , 2020, 26, 256-267.	1.3	17
61	Adherence profiles in kidney transplant patients: Causes and consequences. <i>Patient Education and Counseling</i> , 2020, 103, 189-198.	1.0	34
62	Long-term, prolonged-release tacrolimus-based immunosuppression in de novo kidney transplant recipients: 5-year prospective follow-up of the ADHERE study patients. <i>Transplant International</i> , 2020, 33, 161-173.	0.8	5
63	Hepatitis E virus replication in human intestinal cells. <i>Gut</i> , 2020, 69, 901-910.	6.1	58
64	Does HEV-3 subtype play a role in the severity of acute hepatitis E?. <i>Liver International</i> , 2020, 40, 333-337.	1.9	20
65	Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 1204-1211.	2.9	74
66	Possible patient to patient transmission of progressive multifocal leukoencephalopathy among kidney-transplant patients. <i>Brazilian Journal of Infectious Diseases</i> , 2020, 24, 473-474.	0.3	1
67	Combined Liver-Kidney Transplantation With Preformed Anti-human Leukocyte Antigen Donor-Specific Antibodies. <i>Kidney International Reports</i> , 2020, 5, 2202-2211.	0.4	6
68	Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19. <i>Annals of Internal Medicine</i> , 2020, 173, 501-503.	2.0	21
69	A Randomized Prospective Study Comparing Anti-T-Lymphocyte Igs to Basiliximab in Highly Sensitized Kidney Transplant Patients. <i>Kidney International Reports</i> , 2020, 5, 1207-1217.	0.4	1
70	Hepatitis E Virus: How It Escapes Host Innate Immunity. <i>Vaccines</i> , 2020, 8, 422.	2.1	13
71	Kidney transplantation improves the clinical outcomes of Acute Intermittent Porphyria. <i>Molecular Genetics and Metabolism</i> , 2020, 131, 259-266.	0.5	7
72	An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. <i>Kidney International</i> , 2020, 98, 1549-1558.	2.6	213

#	ARTICLE	IF	CITATIONS
73	Autoantibodies against granulocyte macrophage colony-stimulating factor and <i>Nocardia</i> infection in solid organ transplant recipients. <i>Transplant International</i> , 2020, 33, 1827-1829.	0.8	1
74	Prospects for improved glomerular filtration rate estimation based on creatinine results from a transnational multicentre study. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 674-683.	1.4	11
75	Conversion From Belatacept to Another Immunosuppressive Regimen in Maintenance Kidney-Transplantation Patients. <i>Kidney International Reports</i> , 2020, 5, 2195-2201.	0.4	4
76	IMPact of the COVID-19 epidemic on the moRTALity of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT). <i>Kidney International</i> , 2020, 98, 1568-1577.	2.6	85
77	Cardiac impact of arteriovenous fistulas: what tools to assess?. <i>Heart and Vessels</i> , 2020, 35, 1583-1593.	0.5	4
78	Specific organization for in-hospital belatacept infusion to avoid nosocomial transmission during the SARS-CoV-2 pandemic. <i>American Journal of Transplantation</i> , 2020, 20, 2962-2963.	2.6	7
79	Insertions and Duplications in the Polyproline Region of the Hepatitis E Virus. <i>Frontiers in Microbiology</i> , 2020, 11, 1.	1.5	599
80	Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections. <i>Journal of Clinical Medicine</i> , 2020, 9, 331.	1.0	73
81	An extension of the RITUXERAH study, multicenter randomized clinical trial comparing rituximab to placebo in acute antibody-mediated rejection after renal transplantation. <i>Transplant International</i> , 2020, 33, 786-795.	0.8	18
82	The FcγRIIIA V158 VV genotype increased the risk of post-transplant lymphoproliferative disorder in T cell-depleted kidney transplant recipients – a retrospective study. <i>Transplant International</i> , 2020, 33, 936-947.	0.8	3
83	Hepatitis E Infections in Transplants. , 2020, , 1-18.		1
84	Outcomes with Tacrolimus-Based Immunosuppression After Kidney Transplantation from Standard- and Extended-Criteria Donors – A Post Hoc Analysis of the Prospective OSAKA Study. <i>Annals of Transplantation</i> , 2020, 25, e920041.	0.5	1
85	Comparison of graft and patient survival according to the transplantation centre policy for 1-year screening biopsy among stable kidney recipients: a propensity score-based study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 703-711.	0.4	9
86	Acute and Persistent Hepatitis E Virus Genotype 3 and 4 Infection: Clinical Features, Pathogenesis, and Treatment. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a031872.	2.9	43
87	Incidence, predictors and prognosis of genotype 4 hepatitis E related liver failure: A tertiary nested case-control study. <i>Liver International</i> , 2019, 39, 2291-2300.	1.9	15
88	Anti-CD28 blockers comparing with polyclonal antibodies: Higher risk of rejection without negative mid-term outcomes after ABO-incompatible kidney transplantation. <i>Clinical Transplantation</i> , 2019, 33, e13681.	0.8	4
89	Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin. <i>Viruses</i> , 2019, 11, 630.	1.5	9
90	Outcomes of kidney transplant recipients admitted to the intensive care unit: a retrospective study of 200 patients. <i>BMC Anesthesiology</i> , 2019, 19, 130.	0.7	10

#	ARTICLE	IF	CITATIONS
91	Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients. <i>Transplantation Reviews</i> , 2019, 33, 191-199.	1.2	12
92	Early Switch From Tacrolimus to Everolimus After Liver Transplantation: Outcomes at 2 Years. <i>Liver Transplantation</i> , 2019, 25, 1822-1832.	1.3	26
93	Laparoscopy for living donor left nephrectomy: Comparison of three-dimensional and two-dimensional vision. <i>Clinical Transplantation</i> , 2019, 33, e13745.	0.8	4
94	Early necrotic skin lesions after a ABO-incompatible kidney transplantation: The threat of Cunninghamella Spp.. <i>Transplant Infectious Disease</i> , 2019, 21, e13173.	0.7	1
95	Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy. <i>Emerging Infectious Diseases</i> , 2019, 25, 2145-2147.	2.0	24
96	Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. <i>BMJ: British Medical Journal</i> , 2019, 366, l4923.	2.4	191
97	Hepatitis E virus infections in Europe. <i>Journal of Clinical Virology</i> , 2019, 120, 20-26.	1.6	46
98	Failure to respond to ribavirin despite elevated intraerythrocyte zinc level in transplant patients with chronic hepatitis E virus infection. <i>Transplant Infectious Disease</i> , 2019, 21, e13050.	0.7	9
99	Transfusion-Transmitted Hepatitis E Virus Infection in France. <i>Transfusion Medicine Reviews</i> , 2019, 33, 146-153.	0.9	49
100	Screening, diagnosis and risks associated with Hepatitis E virus infection. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 403-418.	2.0	23
101	Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant Recipients. <i>Clinical Therapeutics</i> , 2019, 41, 882-896.e3.	1.1	5
102	An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients. <i>Kidney International</i> , 2019, 96, 231-244.	2.6	69
103	Seroprevalence of hepatitis E virus (HEV) in a general adult population in Northern Norway: the TromsÅ study. <i>Medical Microbiology and Immunology</i> , 2019, 208, 715-725.	2.6	12
104	Dynamic predictions of long-term kidney graft failure: an information tool promoting patient-centred care. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1961-1969.	0.4	13
105	Should 12- or 24-week post-ribavirin follow-up be considered to define sustained virological response in transplant patients treated for chronic hepatitis E virus infection?. <i>Transplant Infectious Disease</i> , 2019, 21, e13065.	0.7	4
106	Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation. <i>Journal of Hepatology</i> , 2019, 70, 831-838.	1.8	18
107	Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference. <i>Journal of Hepatology</i> , 2019, 70, 1297-1300.	1.8	2
108	No evidence of occult hepatitis C or E virus infections in liver transplant patients with sustained virological response after therapy with direct acting agents. <i>Transplant Infectious Disease</i> , 2019, 21, e13093.	0.7	4

#	ARTICLE	IF	CITATIONS
109	Impact of estimation versus direct measurement of predonation glomerular filtration rate on the eligibility of potential living kidney donors. <i>Kidney International</i> , 2019, 95, 896-904.	2.6	31
110	No Clear Evidence for an Effect of Sofosbuvir Against Hepatitis E Virus in Organ Transplant Patients. <i>Hepatology</i> , 2019, 69, 1846-1847.	3.6	14
111	Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study. <i>Advances in Therapy</i> , 2019, 36, 462-477.	1.3	25
112	Hepatitis E virus genotype 3 and capsid protein in the blood and urine of immunocompromised patients. <i>Journal of Infection</i> , 2019, 78, 232-240.	1.7	31
113	Monitoring hepatitis E virus fecal shedding to optimize ribavirin treatment duration in chronically infected transplant patients. <i>Journal of Hepatology</i> , 2019, 70, 206-209.	1.8	26
114	Prevention and Treatment of Viral Hepatitis. , 2019, , 131-144.		0
115	Direct-acting antivirals and hepatitis B virus (<scp>HBV</scp>) reactivation in co-infected <scp>HBV</scp>/<scp>HCV</scp> kidney-transplant recipients. <i>Transplant Infectious Disease</i> , 2018, 20, e12864.	0.7	7
116	Dosing ribavirin in hepatitis E-infected solid organ transplant recipients. <i>Pharmacological Research</i> , 2018, 130, 308-315.	3.1	16
117	12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation. <i>Hepatology</i> , 2018, 68, 1277-1287.	3.6	11
118	EASL Clinical Practice Guidelines on hepatitis E virus infection. <i>Journal of Hepatology</i> , 2018, 68, 1256-1271.	1.8	425
119	Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 620-635.	3.0	94
120	Safety of renal transplantation in patients with bipolar or psychotic disorders: a retrospective study. <i>Transplant International</i> , 2018, 31, 377-385.	0.8	12
121	Preemptive second kidney transplantation is associated with better graft survival compared with non-preemptive second transplantation: a multicenter French 2000-2014 cohort study. <i>Transplant International</i> , 2018, 31, 408-423.	0.8	22
122	Should Persistent Hepatitis E Virus Replication in Transplant Patients Be Tolerated?. <i>Transplantation</i> , 2018, 102, e84-e85.	0.5	1
123	Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results. <i>Journal of Clinical Oncology</i> , 2018, 36, 2612-2620.	0.8	74
124	Performance of a commercial assay for detecting and quantifying HEV RNA in faeces. <i>Journal of Clinical Virology</i> , 2018, 109, 1-5.	1.6	6
125	Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management. <i>Kidney International</i> , 2018, 94, 663-673.	2.6	72
126	Reply to: "Association of hepatitis E virus infection and myasthenia gravis: A pilot study". <i>Journal of Hepatology</i> , 2018, 68, 1321-1322.	1.8	0



#	ARTICLE	IF	CITATIONS
127	Hepatitis E virus-associated cryoglobulinemia in solid organ transplant recipients. <i>Liver International</i> , 2018, 38, 2178-2189.	1.9	29
128	Impact of donor BK polyomavirus replication on recipient infections in living donor transplantation. <i>Transplant Infectious Disease</i> , 2018, 20, e12917.	0.7	10
129	Diversity of hepatitis E virus genotype 3. <i>Reviews in Medical Virology</i> , 2018, 28, e1987.	3.9	33
130	Actinomycosis: An infrequent disease in renal transplant recipients?. <i>Transplant Infectious Disease</i> , 2018, 20, e12970.	0.7	7
131	Acute hepatitis E in French patients and neurological manifestations. <i>Journal of Infection</i> , 2018, 77, 220-226.	1.7	51
132	Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective. <i>Kidney International</i> , 2018, 94, 206-213.	2.6	18
133	The age-calibrated measured glomerular filtration rate improves living kidney donation selection process. <i>Kidney International</i> , 2018, 94, 616-624.	2.6	28
134	Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw348.	0.4	46
135	Direct-acting antiviral therapy for hepatitis E virus?. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 154-155.	3.7	11
136	Predictive model of 1-year postoperative renal function after living donor nephrectomy. <i>International Urology and Nephrology</i> , 2017, 49, 793-801.	0.6	11
137	RIC is a key antiviral interferon-stimulated gene against hepatitis E virus regardless of interferon production. <i>Hepatology</i> , 2017, 65, 1823-1839.	3.6	63
138	Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients. <i>Transplantation</i> , 2017, 101, S1-S56.	0.5	217
139	Malignancies in hepatitis C virus-positive and -negative kidney transplant recipients: A case-controlled study. <i>Transplant Infectious Disease</i> , 2017, 19, e12725.	0.7	3
140	Impact of transplant accessibility for sensitized patients by avoiding unacceptable antigens. <i>Liver Transplantation</i> , 2017, 23, 880-886.	1.3	3
141	Three-dimensional laparoscopy for living-donor nephrectomy with vaginal extraction: The first case. <i>International Journal of Surgery Case Reports</i> , 2017, 34, 87-89.	0.2	4
142	Detection of viral hepatitis E in clinical liver biopsies. <i>Histopathology</i> , 2017, 71, 580-590.	1.6	11
143	Hepatitis E Virus Infects Neurons and Brains. <i>Journal of Infectious Diseases</i> , 2017, 215, 1197-1206.	1.9	94
144	Transfusion-acquired hepatitis E infection misdiagnosed as severe critical illness polyneuromyopathy in a heart transplant patient. <i>Transplant Infectious Disease</i> , 2017, 19, e12784.	0.7	14

#	ARTICLE	IF	CITATIONS
145	Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUIPILT study. <i>American Journal of Transplantation</i> , 2017, 17, 2869-2878.	2.6	6
146	Hepatitis E virus infection and acute non-traumatic neurological injury: A prospective multicentre study. <i>Journal of Hepatology</i> , 2017, 67, 925-932.	1.8	80
147	Clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy. <i>Neurology</i> , 2017, 89, 909-917.	1.5	75
148	Hepatitis E virus infection. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17086.	18.1	386
149	Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab. <i>Clinical Immunology</i> , 2017, 183, 1-7.	1.4	16
150	Histological long-term outcomes from acute antibody-mediated rejection following ABO-compatible liver transplantation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 887-893.	1.4	13
151	Sofosbuvir and Daclatasvir Anti-Viral Therapy Fails to Clear HEV Viremia and Restore Reactive T Cells in a HEV/HCV Co-Infected Liver Transplant Recipient. <i>Gastroenterology</i> , 2017, 152, 300-301.	0.6	51
152	Hepatitis E Virus Infection in Solid Organ Transplant Recipients, France. <i>Emerging Infectious Diseases</i> , 2017, 23, 353-356.	2.0	25
153	Unusual Pathology in a Kidney from a Heart-Transplant Patient. <i>Case Reports in Transplantation</i> , 2017, 2017, 1-3.	0.1	0
154	Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation. <i>Case Reports in Transplantation</i> , 2017, 2017, 1-6.	0.1	8
155	Rabbit Hepatitis E Virus Infections in Humans, France. <i>Emerging Infectious Diseases</i> , 2017, 23, 1191-1193.	2.0	139
156	Treatment of HEV Infection in Patients with a Solid-Organ Transplant and Chronic Hepatitis. <i>Viruses</i> , 2016, 8, 222.	1.5	36
157	Hepatitis E Pathogenesis. <i>Viruses</i> , 2016, 8, 212.	1.5	77
158	Quantification of HEV RNA by Droplet Digital PCR. <i>Viruses</i> , 2016, 8, 233.	1.5	26
159	Calcineurin Inhibitors Downregulate HNF-1 $\beta$ and May Affect the Outcome of HNF1B Patients After Renal Transplantation. <i>Transplantation</i> , 2016, 100, 1970-1978.	0.5	6
160	Extrahepatic manifestations of hepatitis E virus. <i>Liver International</i> , 2016, 36, 467-472.	1.9	98
161	Evolution and Determinants of Health-Related Quality-of-Life in Kidney Transplant Patients Over the First 3 Years After Transplantation. <i>Transplantation</i> , 2016, 100, 640-647.	0.5	29
162	Treatment of autochthonous acute hepatitis E with short-term ribavirin: a multicenter retrospective study. <i>Liver International</i> , 2016, 36, 328-333.	1.9	61

#	ARTICLE	IF	CITATIONS
163	Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viremia and/or viremia. <i>Transplant International</i> , 2016, 29, 315-322.	0.8	21
164	<i>Nocardia</i> Infection in Solid Organ Transplant Recipients: A Multicenter European Case-control Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 338-345.	2.9	179
165	A 3-month course of ciprofloxacin does not prevent BK virus replication in heavily immunosuppressed kidney-transplant patients. <i>Journal of Clinical Virology</i> , 2016, 79, 61-67.	1.6	13
166	Characterization of the Specificity, Functionality, and Durability of Host T-Cell Responses Against the Full-Length Hepatitis E Virus. <i>Hepatology</i> , 2016, 64, 1934-1950.	3.6	42
167	Late isolated ocular toxoplasmosis in a belatacept-treated kidney transplant patient. <i>Transplant International</i> , 2016, 29, 1352-1353.	0.8	8
168	Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation. <i>Liver Transplantation</i> , 2016, 22, 1367-1378.	1.3	32
169	Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients. <i>Transplant International</i> , 2016, 29, 1257-1265.	0.8	11
170	Treatment of hepatitis E virus. <i>Current Opinion in Infectious Diseases</i> , 2016, 29, 639-644.	1.3	31
171	Successful pregnancy after ABO-incompatible kidney transplantation. <i>Transplant International</i> , 2016, 29, 506-507.	0.8	4
172	Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence – The ANRS CUPILT study. <i>Journal of Hepatology</i> , 2016, 65, 711-718.	1.8	72
173	No evidence of genotype-3 hepatitis E virus-induced myocarditis. <i>Journal of Clinical Virology</i> , 2016, 76, 44.	1.6	1
174	Performance of an antigen assay for diagnosing acute hepatitis E virus genotype 3 infection. <i>Journal of Clinical Virology</i> , 2016, 79, 1-5.	1.6	44
175	Belatacept prophylaxis against organ rejection in adult kidney-transplant recipients. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 215-227.	1.3	6
176	Hepatitis E in Transplantation. <i>Current Infectious Disease Reports</i> , 2016, 18, 8.	1.3	14
177	Donor-specific antibodies and liver transplantation. <i>Human Immunology</i> , 2016, 77, 1063-1070.	1.2	44
178	Conventional and innate lymphocytes response at the acute phase of HEV infection in transplanted patients. <i>Journal of Infection</i> , 2016, 72, 723-730.	1.7	25
179	Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1608-1614.	1.4	62
180	Hepatitis E Virus-Induced Cryoglobulinemic Glomerulonephritis in a Nonimmunocompromised Person. <i>American Journal of Kidney Diseases</i> , 2016, 67, 660-663.	2.1	58

#	ARTICLE	IF	CITATIONS
181	Hepatitis E virus and neurological injury. <i>Nature Reviews Neurology</i> , 2016, 12, 77-85.	4.9	198
182	Early post-transplant complications following ABO-incompatible kidney transplantation. <i>Journal of Nephropathology</i> , 2016, 5, 19-27.	0.1	7
183	Dosing of Enteric-Coated Mycophenolate Sodium Under Routine Conditions: An Observational, Multicenter Study in Kidney Transplantation. <i>Annals of Transplantation</i> , 2016, 21, 250-261.	0.5	0
184	Belatacept in recurrent focal segmental glomerulosclerosis after kidney transplantation. <i>Transplant International</i> , 2015, 28, 1109-1110.	0.8	19
185	De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients. <i>Transplant International</i> , 2015, 28, 1371-1382.	0.8	70
186	An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients. <i>Transplantation</i> , 2015, 99, 2124-2131.	0.5	60
187	Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation. <i>Transplant International</i> , 2015, 28, 928-937.	0.8	11
188	Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies. <i>Emerging Infectious Diseases</i> , 2015, 21, 1466-1469.	2.0	41
189	Pneumocystis Pneumonia in Solid-Organ Transplant Recipients. <i>Journal of Fungi (Basel, Switzerland)</i> , 2015, 1, 293-331.	1.5	54
190	Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates. <i>Journal of Transplantation</i> , 2015, 2015, 1-5.	0.3	5
191	Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1993-2001.e2.	2.4	118
192	Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. <i>BMJ, The</i> , 2015, 351, h3557.	3.0	146
193	Pretransplant urinary proteome analysis does not predict development of chronic kidney disease after liver transplantation. <i>Liver International</i> , 2015, 35, 1893-1901.	1.9	6
194	Temporal evolution of the distribution of hepatitis E virus genotypes in Southwestern France. <i>Infection, Genetics and Evolution</i> , 2015, 35, 50-55.	1.0	33
195	Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation. <i>Transplant International</i> , 2015, 28, 255-258.	0.8	22
196	Hepatitis E: The Commonest Viral Zoonosis Worldwide?. , 2015, , 915-935.		0
197	Interference of therapeutic antibodies used in desensitization protocols on lymphocytotoxicity crossmatch results. <i>Transplant Immunology</i> , 2015, 32, 151-155.	0.6	18
198	Performance of a new rapid test for detecting anti-hepatitis E virus immunoglobulin M in immunocompetent and immunocompromised patients. <i>Journal of Clinical Virology</i> , 2015, 70, 101-104.	1.6	19

#	ARTICLE	IF	CITATIONS
199	Protracted Fecal Shedding of HEV During Ribavirin Therapy Predicts Treatment Relapse. <i>Clinical Infectious Diseases</i> , 2015, 60, 96-99.	2.9	62
200	Hepatitis E virus: Chronic infection, extra-hepatic manifestations, and treatment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 20-27.	0.7	78
201	Each additional hour of cold ischemia time significantly increases the risk of graft failure and mortality following renal transplantation. <i>Kidney International</i> , 2015, 87, 343-349.	2.6	287
202	An Association between BK Virus Replication in Bone Marrow and Cytopenia in Kidney-Transplant Recipients. <i>Journal of Transplantation</i> , 2014, 2014, 1-9.	0.3	7
203	Influence of Polyproline Region and Macro Domain Genetic Heterogeneity on HEV Persistence in Immunocompromised Patients. <i>Journal of Infectious Diseases</i> , 2014, 209, 300-303.	1.9	53
204	Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration Rate. <i>Case Reports in Transplantation</i> , 2014, 2014, 1-4.	0.1	8
205	Incidence of anti-HLA donor specific antibodies in liver-transplant patients given mTOR inhibitors without calcineurin inhibitors. <i>Journal of Hepatology</i> , 2014, 61, 963-965.	1.8	8
206	Ribavirin for Chronic Hepatitis E Virus Infection. <i>New England Journal of Medicine</i> , 2014, 370, 2446-2448.	13.9	33
207	Hepatitis E in developed countries: current status and future perspectives. <i>Future Microbiology</i> , 2014, 9, 1361-1372.	1.0	49
208	Pregnancy after kidney transplantation: outcome and anti-human leucocyte antigen alloimmunization risk. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1786-1793.	0.4	26
209	Isolated Aspergillosis Myocardial Abscesses in a Liver-Transplant Patient. <i>Case Reports in Transplantation</i> , 2014, 2014, 1-3.	0.1	5
210	Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients. <i>New England Journal of Medicine</i> , 2014, 370, 1111-1120.	13.9	436
211	Does chronic hepatitis E virus infection exist in immunocompetent patients?. <i>Hepatology</i> , 2014, 60, 427-427.	3.6	17
212	Hepatitis E Virus Infection. <i>Clinical Microbiology Reviews</i> , 2014, 27, 116-138.	5.7	512
213	CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality. <i>Transplant International</i> , 2014, 27, 956-965.	0.8	38
214	Characterization of the Polyproline Region of the Hepatitis E Virus in Immunocompromised Patients. <i>Journal of Virology</i> , 2014, 88, 12017-12025.	1.5	58
215	A prospective study in male recipients of kidney transplantation reveals divergent patterns for inhibin B and testosterone secretions. <i>Basic and Clinical Andrology</i> , 2014, 24, 11.	0.8	9
216	Hepatitis E Virus Re-infections in Solid-Organ-Transplant Recipients Can Evolve Into Chronic Infections. <i>Journal of Infectious Diseases</i> , 2014, 209, 1900-1906.	1.9	136

#	ARTICLE	IF	CITATIONS
217	Influence of Anemia on Patient and Graft Survival After Renal Transplantation. <i>Transplantation</i> , 2014, 97, 168-175.	0.5	17
218	Chronic Hepatitis E Virus Infection and Treatment. <i>Journal of Clinical and Experimental Hepatology</i> , 2013, 3, 134-140.	0.4	60
219	Performance of anti-HEV assays for diagnosing acute hepatitis E in immunocompromised patients. <i>Journal of Clinical Virology</i> , 2013, 58, 624-628.	1.6	98
220	Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen. <i>Clinical Transplantation</i> , 2013, 27, 455-462.	0.8	45
221	Low- versus high-dose rituximab for antibody-mediated rejection after kidney transplantation. <i>Transplant International</i> , 2013, 26, e12-e14.	0.8	6
222	Hepatitis C virus and kidney disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 328-333.	0.7	17
223	Hepatitis E virus infection. <i>Current Opinion in Gastroenterology</i> , 2013, 29, 271-278.	1.0	36
224	Hepatitis E Virus Infection in Immunosuppressed Patients: Natural History and Therapy. <i>Seminars in Liver Disease</i> , 2013, 33, 062-070.	1.8	82
225	Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 734-740.	1.1	68
226	Everolimus-induced recurrent pericardial effusion after kidney transplantation. <i>Transplant International</i> , 2013, 26, e36-e37.	0.8	5
227	Performance of Two Commercial Assays for Detecting Hepatitis E Virus RNA in Acute or Chronic Infections. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1913-1916.	1.8	48
228	Hepatitis C virus infection in nephrology patients. <i>Journal of Nephropathology</i> , 2013, 2, 217-33.	0.1	11
229	Donor-Specific Antibodies after Ceasing Immunosuppressive Therapy, with or without an Allograft Nephrectomy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1310-1319.	2.2	77
230	Hepatitis E Virus Quasispecies and the Outcome of Acute Hepatitis E in Solid-Organ Transplant Patients. <i>Journal of Virology</i> , 2012, 86, 10006-10014.	1.5	97
231	Hepatitis E Virus and the Kidney in Solid-Organ Transplant Patients. <i>Transplantation</i> , 2012, 93, 617-623.	0.5	170
232	Hepatitis E. <i>Lancet</i> , The, 2012, 379, 2477-2488.	6.3	805
233	Hepatitis E virus-induced severe myositis. <i>Journal of Hepatology</i> , 2012, 57, 1152-1153.	1.8	58
234	Low risk of hepatitis E virus reactivation after haematopoietic stem cell transplantation. <i>Journal of Clinical Virology</i> , 2012, 54, 152-155.	1.6	56

#	ARTICLE	IF	CITATIONS
235	Poor Long-Term Outcome in Second Kidney Transplantation: A Delayed Event. PLoS ONE, 2012, 7, e47915.	1.1	25
236	Hepatitis E Virus Strains in Rabbits and Evidence of a Closely Related Strain in Humans, France. Emerging Infectious Diseases, 2012, 18, 1274-81.	2.0	221
237	Hepatitis E virus-specific T-cell response after transplantation. Hepatology, 2012, 55, 1643-1643.	3.6	8
238	Impact of post-transplant anemia on patient and graft survival rates after kidney transplantation: a meta-analysis. Clinical Transplantation, 2012, 26, 461-469.	0.8	23
239	Do kidney histology lesions predict long-term kidney function after liver transplantation?. Clinical Transplantation, 2012, 26, 927-934.	0.8	6
240	Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study. Transplant International, 2012, 25, 1059-1064.	0.8	47
241	A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients. Clinical Nephrology, 2012, 77, 126-136.	0.4	19
242	Factors Associated With Chronic Hepatitis in Patients With Hepatitis E Virus Infection Who Have Received Solid Organ Transplants. Gastroenterology, 2011, 140, 1481-1489.	0.6	570
243	Inhibition of T-cell activation and proliferation by mycophenolic acid in patients awaiting liver transplantation: PK/PD relationships. Pharmacological Research, 2011, 63, 432-438.	3.1	21
244	Hepatitis E Virus Infection without Reactivation in Solid-Organ Transplant Recipients, France. Emerging Infectious Diseases, 2011, 17, 30-37.	2.0	134
245	Hepatitis E Virus and Neurologic Disorders. Emerging Infectious Diseases, 2011, 17, 173-179.	2.0	279
246	Hepatitis E Virus Antibodies in Blood Donors, France. Emerging Infectious Diseases, 2011, 17, 2309-2312.	2.0	314
247	New-Onset Diabetes and Nephropathy after Renal Transplantation. Contributions To Nephrology, 2011, 170, 247-255.	1.1	22
248	Kidney histology and function in liver transplant patients. Nephrology Dialysis Transplantation, 2011, 26, 2355-2361.	0.4	14
249	Definitive Clearance of a Chronic Hepatitis E Virus Infection With Ribavirin Treatment. American Journal of Gastroenterology, 2011, 106, 1562-1563.	0.2	43
250	Hepatitis E virus infection in Iranian kidney-transplant patients. Hepatitis Monthly, 2011, 11, 927-928.	0.1	5
251	Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrology Dialysis Transplantation, 2011, 26, 2309-2316.	0.4	53
252	Alveolar and Blood T Lymphocyte Profiles in Pneumocystis jirovecii-Positive Patients: Effects of HIV Status. Journal of Infectious Diseases, 2011, 204, 544-553.	1.9	12

#	ARTICLE	IF	CITATIONS
253	Hepatitis E Virus Infection in Iranian Kidney-Transplant Patients. <i>Hepatitis Monthly</i> , 2011, 11, 927-928.	0.1	2
254	No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. <i>Transplant International</i> , 2010, 23, 594-601.	0.8	54
255	Assessing Renal Function With Daclizumab Induction and Delayed Tacrolimus Introduction in Liver Transplant Recipients. <i>Transplantation</i> , 2010, 89, 1504-1510.	0.5	50
256	Belatacept-Based Regimens Versus a Cyclosporine A-Based Regimen in Kidney Transplant Recipients: 2-Year Results From the BENEFIT and BENEFIT-EXT Studies. <i>Transplantation</i> , 2010, 90, 1528-1535.	0.5	156
257	Influence of Immunosuppressive Therapy on the Natural History of Genotype 3 Hepatitis-E Virus Infection After Organ Transplantation. <i>Transplantation</i> , 2010, 89, 353-360.	0.5	201
258	Chronic Hepatitis E Virus Infection: Successful Virologic Response to Pegylated Interferon- $\alpha$ Therapy. <i>Annals of Internal Medicine</i> , 2010, 153, 135.	2.0	66
259	Characteristics of Autochthonous Hepatitis E Virus Infection in Solid-Organ Transplant Recipients in France. <i>Journal of Infectious Diseases</i> , 2010, 202, 835-844.	1.9	174
260	Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. <i>Liver Transplantation</i> , 2010, 16, 74-82.	1.3	176
261	Impact of very early high doses of recombinant erythropoietin on anemia and allograft function in de novo kidney-transplant patients. <i>Transplant International</i> , 2010, 23, 277-284.	0.8	16
262	Pegylated Interferon- $\alpha$ for Treating Chronic Hepatitis E Virus Infection after Liver Transplantation. <i>Clinical Infectious Diseases</i> , 2010, 50, e30-e33.	2.9	180
263	Treatment of Chronic Hepatitis C Virus Infection in Dialysis Patients: An Update. <i>Hepatitis Research and Treatment</i> , 2010, 2010, 1-6.	2.0	6
264	Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2792-2795.	0.4	92
265	Ribavirin Therapy Inhibits Viral Replication on Patients With Chronic Hepatitis E Virus Infection. <i>Gastroenterology</i> , 2010, 139, 1612-1618.	0.6	265
266	Pre-emptive intravenous ganciclovir versus valganciclovir prophylaxis for de novo cytomegalovirus-seropositive kidney-transplant recipients. <i>Transplant International</i> , 2010, 23, 1056-1064.	0.8	19
267	mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?. <i>Journal of Nephrology</i> , 2010, 23, 133-42.	0.9	59
268	Good Performance of Immunoglobulin M Assays in Diagnosing Genotype 3 Hepatitis E Virus Infections. <i>Vaccine Journal</i> , 2009, 16, 772-774.	3.2	80
269	Hepatitis E Virus Genotype 3 Diversity, France. <i>Emerging Infectious Diseases</i> , 2009, 15, 110-114.	2.0	141
270	Pharmacodynamic Evaluation of the First Dose of Mycophenolate Mofetil Before Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 936-942.	2.2	24



#	ARTICLE	IF	CITATIONS
271	Occult Hepatitis C Virus Infection in Hemodialysis Patients: Examining the Evidence. <i>American Journal of Kidney Diseases</i> , 2009, 54, 10-12.	2.1	13
272	Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis. <i>Transplant International</i> , 2009, 22, 568-573.	0.8	28
273	Cytokines correlate with age in healthy volunteers, dialysis patients and kidney-transplant patients. <i>Cytokine</i> , 2009, 45, 169-173.	1.4	21
274	Polyoma BK virus-associated nephropathy in kidney-transplant patients: Effects of leflunomide on T-cell functions and disease outcome. <i>International Immunopharmacology</i> , 2009, 9, 1131-1136.	1.7	16
275	Rituximab for Humoral Rejection After Kidney Transplantation: An Update. <i>Transplantation</i> , 2009, 87, 1261.	0.5	20
276	Mycophenolic Acid 12-Hour Area Under the Curve in De Novo Liver Transplant Patients Given Mycophenolate Mofetil at Fixed Versus Concentration-Controlled Doses. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 451-456.	1.0	7
277	Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation. <i>World Journal of Gastroenterology</i> , 2009, 15, 3426.	1.4	41
278	Predictive factors for cytomegalovirus reactivation in cytomegalovirus- $\epsilon$ seropositive kidney- $\epsilon$ transplant patients. <i>Journal of Medical Virology</i> , 2008, 80, 1012-1017.	2.5	23
279	Cytomegalovirus prophylaxis with valganciclovir in cytomegalovirus- $\epsilon$ seropositive kidney- $\epsilon$ transplant patients. <i>Journal of Medical Virology</i> , 2008, 80, 1228-1232.	2.5	13
280	Successful Retransplantation of a Kidney Allograft Affected by Thrombotic Microangiopathy Into a Second Transplant Recipient. <i>American Journal of Kidney Diseases</i> , 2008, 52, 591-594.	2.1	12
281	Hepatitis E Virus and Chronic Hepatitis in Organ-Transplant Recipients. <i>New England Journal of Medicine</i> , 2008, 358, 811-817.	13.9	1,197
282	Pharmacodynamic effects of cinacalcet after kidney transplantation: once- versus twice-daily dose. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3720-3726.	0.4	23
283	Negative Impact of One-Year Anemia on Long-Term Patient and Graft Survival in Kidney Transplant Patients Receiving Calcineurin Inhibitors and Mycophenolate Mofetil. <i>Transplantation</i> , 2008, 85, 1120-1124.	0.5	51
284	Predictive Factors for Posttransplant Diabetes Mellitus Within One-Year of Liver Transplantation. <i>Transplantation</i> , 2008, 85, 1436-1442.	0.5	47
285	Entecavir Therapy for Adefovir-Resistant Hepatitis B Virus Infection in Kidney and Liver Allograft Recipients. <i>Transplantation</i> , 2008, 86, 611-614.	0.5	65
286	Diabetes mellitus after kidney transplantation: a French multicentre observational study. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 1986-1993.	0.4	85
287	Alpha-interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 1043-1047.	0.4	34
288	Rituximab Therapy for Acute Humoral Rejection After Kidney Transplantation. <i>Transplantation</i> , 2007, 83, 1277-1280.	0.5	194

#	ARTICLE	IF	CITATIONS
289	Validation of Immunological Biomarkers for the Pharmacodynamic Monitoring of Immunosuppressive Drugs in Humans. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 77-86.	1.0	60
290	Evaluation of the efficacy and safety of a slow conversion from calcineurin inhibitor- to sirolimus-based therapies in maintenance renal-transplant patients presenting with moderate renal insufficiency. <i>Transplant International</i> , 2007, 20, 128-34.	0.8	14
291	Liver histology in patients with sporadic acute hepatitis E: a study of 11 patients from South-West France. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 450, 405-410.	1.4	62
292	Predictive Factors for Chronic Renal Failure One Year after Orthotopic Liver Transplantation. <i>Renal Failure</i> , 2006, 28, 419-425.	0.8	33
293	Treatment of Hepatitis C Virus Infection (HCV) After Renal Transplantation: Implications for HCV-Positive Dialysis Patients Awaiting a Kidney Transplant. <i>Transplantation</i> , 2006, 82, 853-856.	0.5	61
294	Effects of intraoperative versus postoperative administration of rabbit antithymocyte antibodies on 1-year renal function in renal transplant patients. <i>Experimental and Clinical Transplantation</i> , 2006, 4, 429-38.	0.2	0
295	Impact of mycophenolic acid dose modifications on renal function after kidney transplantation. <i>Experimental and Clinical Transplantation</i> , 2006, 4, 510-7.	0.2	0
296	Renal function and histology in kidney transplant patients receiving tacrolimus and sirolimus or mycophenolate mofetil. <i>Experimental and Clinical Transplantation</i> , 2006, 4, 532-6.	0.2	0
297	Predictive Factors of Anemia within the First Year Post Renal Transplant. <i>Transplantation</i> , 2005, 80, 903-909.	0.5	34
298	Rituximab Therapy for De Novo Mixed Cryoglobulinemia in Renal Transplant Patients. <i>Transplantation</i> , 2005, 80, 1560-1564.	0.5	76
299	Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C. <i>Clinical Transplantation</i> , 2005, 19, 83-89.	0.8	19
300	Acute hepatitis and renal function impairment related to infection by hepatitis E virus in a renal allograft recipient. <i>American Journal of Kidney Diseases</i> , 2005, 45, 193-196.	2.1	55
301	Natural History of Hepatitis C Virus-Related Liver Fibrosis After Renal Transplantation. <i>American Journal of Transplantation</i> , 2005, 5, 1704-1712.	2.6	119
302	Intrahepatic cytokine profile in renal-transplant patients infected by hepatitis C virus. <i>Journal of Medical Virology</i> , 2005, 76, 482-488.	2.5	3
303	Incidence of HCV infection in French hemodialysis units: A prospective study. <i>Journal of Medical Virology</i> , 2005, 77, 70-76.	2.5	75
304	Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. <i>American Journal of Kidney Diseases</i> , 2004, 43, 140-146.	2.1	76
305	Amantadine therapy in renal transplant patients with hepatitis C virus infection. <i>Journal of Clinical Virology</i> , 2004, 30, 110-114.	1.6	39
306	Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. <i>American Journal of Kidney Diseases</i> , 2003, 42, 184-192.	2.1	83

#	ARTICLE	IF	CITATIONS
307	Evolution of hepatitis C virus quasispecies in renal transplant patients with de novo glomerulonephritis. <i>Journal of Medical Virology</i> , 2003, 69, 482-488.	2.5	7
308	Evidence that Clearance of Hepatitis C Virus RNA after $\alpha$ -Interferon Therapy in Dialysis Patients Is Sustained after Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2092-2098.	3.0	173
309	Hepatitis E Virus. , 0, , 1209-1229.		1